Lecia V. Sequist, MD

Lecia V. Sequist, MD, discusses the unanswered question of which EGFR TKI to use in the frontline setting of NSCLC.

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with CO-1686 for patients with non-small cell lung cancer (NSCLC).